Farms.com Home   News

Breakthrough in Brazil - Approval of Dabeinong's GM soybeans

Beijing Dabeinong Technology Group Co Ltd has made headlines in the agricultural world with its latest breakthrough in Brazil. The country has granted approval for the commercial planting of the company's genetically-modified soybean, DBN9004. This decision marks a significant step in modernizing soybean cultivation in South America. 

DBN9004 is designed to resist specific herbicides like glyphosate and glufosinate-ammonium, providing a robust solution to weed control challenges in soybean farms. This trait is particularly advantageous in the context of South American agriculture, where efficient weed management is crucial. 

The recent approval signifies Beijing Dabeinong's first successful venture in Brazil's soybean market. This achievement is anticipated to fuel the company's expansion plans within the country. Previously, the company had made its mark in Argentina by securing approval for its genetically-modified, insect-resistant soybeans in 2022, demonstrating its growing prominence in the South American agricultural sector. 

The endorsement of DBN9004 in Brazil represents not just a triumph for Beijing Dabeinong, but a leap forward for agricultural practices in the region. The introduction of these soybeans could revolutionize farming efficiency and sustainability, providing farmers with a powerful tool in their crop cultivation arsenal. 

Moreover, this development underscores the increasing collaboration and exchange of agricultural technologies between China and South American nations. As such, the approval of DBN9004 is more than a business achievement; it's a testament to the growing synergy in global agricultural innovation and sustainability efforts. 

Source : wisconsinagconnection

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.